Advertisement

Screening for atrial fibrillation: Need for an integrated, structured approach

  • Giuseppe Boriani
    Correspondence
    Corresponding author at: Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41121 Modena, Italy.
    Affiliations
    Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
  • Marco Proietti
    Affiliations
    Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

    Geriatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Liverpool Centre for Cardiovascular Science, University of Liverpool, and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
    Search for articles by this author
      Atrial fibrillation (AF) is a very common disease, particularly in the elderly, and the number of affected patients has been predicted to increase in the next decades [
      • Boriani G.
      • Diemberger I.
      • Martignani C.
      • Biffi M.
      • Branzi A.
      The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems.
      ,
      • Lip G.Y.H.
      • Banerjee A.
      • Boriani G.
      • Chiang C.E.
      • Fargo R.
      • Freedman B.
      • et al.
      Antithrombotic therapy for atrial fibrillation.
      ]. The existence of a link between AF and ischemic stroke is now well established, with AF being present in around 30% of patients reporting an ischemic stroke, as well as with stroke being the first clinical manifestation of previously unknown AF in over 25% of AF-related strokes [
      • Freedman B.
      • Potpara T.S.
      • Lip G.Y.H.
      Stroke prevention in atrial fibrillation.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boriani G.
        • Diemberger I.
        • Martignani C.
        • Biffi M.
        • Branzi A.
        The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems.
        Eur Heart J. 2006; 27: 893-894https://doi.org/10.1093/eurheartj/ehi651
        • Lip G.Y.H.
        • Banerjee A.
        • Boriani G.
        • Chiang C.E.
        • Fargo R.
        • Freedman B.
        • et al.
        Antithrombotic therapy for atrial fibrillation.
        Chest. 2018; 154: 1121-1201https://doi.org/10.1016/j.chest.2018.07.040
        • Freedman B.
        • Potpara T.S.
        • Lip G.Y.H.
        Stroke prevention in atrial fibrillation.
        Lancet. 2016; 388: 806-817https://doi.org/10.1016/S0140-6736(16)31257-0
        • Xiong Q.
        • Proietti M.
        • Senoo K.
        • Lip G.Y.H.
        Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age/gender differences and cardiovascular outcomes.
        Int J Cardiol. 2015; 191: 172-177https://doi.org/10.1016/j.ijcard.2015.05.011
        • Boriani G.
        • Laroche C.
        • Diemberger I.
        • Fantecchi E.
        • Popescu M.I.
        • Rasmussen L.H.
        • et al.
        Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF pilot general registry.
        Am J Med. 2015; 128: 509-518.e2https://doi.org/10.1016/j.amjmed.2014.11.026
        • Siontis K.C.
        • Gersh B.J.
        • Killian J.M.
        • Noseworthy P.A.
        • McCabe P.
        • Weston S.A.
        • et al.
        Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications.
        Hear Rhythm. 2016; 13: 1418-1424https://doi.org/10.1016/j.hrthm.2016.03.003
        • Mairesse G.H.
        • Moran P.
        • Van Gelder I.C.
        • Elsner C.
        • Mant J.
        • Banerjee A.
        • et al.
        Screening for atrial fibrillation: a European heart rhythm association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiolog.
        Europace. 2017; 19: 1-35https://doi.org/10.1093/europace/eux177
        • Freedman B.
        Screening for atrial fibrillation.
        Circulation. 2017; 135: 1851-1867https://doi.org/10.1161/CIRCULATIONAHA.116.026693
        • Hart R.G.
        • Benavente O.
        • McBride R.
        • Pearce L.A.
        Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
        Ann Intern Med. 1999; 131: 492-501
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • Hoffman E.B.
        • Deenadayalu N.
        • Ezekowitz M.D.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962https://doi.org/10.1016/S0140-6736(13)62343-0
        • Freedman B.
        • Martinez C.
        • Katholing A.
        • Rietbrock S.
        Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation.
        JAMA Cardiol. 2016; 1: 366https://doi.org/10.1001/jamacardio.2016.0393
        • Engdahl J.
        • Holmén A.
        • Rosenqvist M.
        • Strömberg U.
        A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation.
        Europace. 2018; 20: f306-f311https://doi.org/10.1093/europace/euy045
        • National Clinical Guideline Centre (NICE)
        Atrial Fibrillation: The Management of Atrial Fibrillation.
        National Clinical Guideline Centre, London2014
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • et al.
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962https://doi.org/10.1093/eurheartj/ehw210
        • NHFA CSANZ Atrial Fibrillation Guideline Working Group D
        • Brieger D.
        • Amerena J.
        • Attia J.
        • Bajorek B.
        • Chan K.H.
        • et al.
        National Heart Foundation of Australia and the Cardiac Society of Australia and new Zealand: Australian clinical guidelines for the diagnosis and Management of Atrial Fibrillation 2018.
        Heart Lung Circ. 2018; 27: 1209-1266https://doi.org/10.1016/j.hlc.2018.06.1043
        • Joung B.
        • Lee J.M.
        • Lee K.H.
        • Kim T.H.
        • Choi E.K.
        • Lim W.H.
        • et al.
        2018 Korean guideline of atrial fibrillation management.
        Korean Circ J. 2018; 48: 1033-1080https://doi.org/10.4070/kcj.2018.0339
        • de Moraes E.
        • Cirenza C.
        • Lopes R.D.
        • Carvalho A.
        • Guimaraes P.
        • Rodrigues A.
        • et al.
        Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting.
        Eur J Intern Med. 2019; (Article in Press)https://doi.org/10.1016/j.ejim.2019.04.024
        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Fauchier L.
        • Marin F.
        • Nabauer M.
        • et al.
        Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational research programme on atrial fibrillation (EORP-AF) long-term general registry.
        Europace. 2018; 20: 747-757https://doi.org/10.1093/europace/eux301
        • Proietti M.
        • Laroche C.
        • Nieuwlaat R.
        • Crijns H.J.G.M.
        • Maggioni A.P.
        • Lane D.A.
        • et al.
        Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries.
        Eur J Intern Med. 2018; 55: 28-34https://doi.org/10.1016/j.ejim.2018.05.016
        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Diemberger I.
        • Popescu M.I.
        • Riahi S.
        • et al.
        Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational research programme on atrial fibrillation (EORP-AF) pilot general r.
        Int J Cardiol. 2018; 271: 68-74https://doi.org/10.1016/j.ijcard.2018.05.034
        • Proietti M.
        • Antoniazzi S.
        • Monzani V.
        • Santalucia P.
        • Franchi C.
        Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.
        Eur J Intern Med. 2018; 52: e12-e14https://doi.org/10.1016/j.ejim.2018.04.006
        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Fauchier L.
        • Marin F.
        • Nabauer M.
        • et al.
        Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry.
        EP Eur. 2019; https://doi.org/10.1093/europace/euz032
        • Orchard J.
        • Lowres N.
        • Neubeck L.
        • Freedman B.
        Atrial fibrillation: is there enough evidence to recommend opportunistic or systematic screening?.
        Int J Epidemiol. 2018; 47: 1361https://doi.org/10.1093/ije/dyy156
        • Proietti M.
        • Mairesse G.H.
        • Goethals P.
        • Scavee C.
        • Vijgen J.
        • Blankoff I.
        • et al.
        A population screening programme for atrial fibrillation: a report from the Belgian heart rhythm week screening programme.
        Europace. 2016; 18: 1779-1786https://doi.org/10.1093/europace/euw069
        • Proietti M.
        • Farcomeni A.
        • Goethals P.
        • Scavee C.
        • Vijgen J.
        • Blankoff I.
        • et al.
        Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: the Belgian heart rhythm week screening programme.
        Eur J Prev Cardiol. 2019; 26: 964-972https://doi.org/10.1177/2047487319839184
        • Curry S.J.
        • Krist A.H.
        • Owens D.K.
        • Barry M.J.
        • Caughey A.B.
        • Davidson K.W.
        • et al.
        Screening for atrial fibrillation with electrocardiography: US preventive services task force recommendation statement.
        JAMA. 2018; 320: 478-484https://doi.org/10.1001/jama.2018.10321

      Linked Article